These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
414 related articles for article (PubMed ID: 25505230)
1. Prognostic significance of POLE proofreading mutations in endometrial cancer. Church DN; Stelloo E; Nout RA; Valtcheva N; Depreeuw J; ter Haar N; Noske A; Amant F; Tomlinson IP; Wild PJ; Lambrechts D; Jürgenliemk-Schulz IM; Jobsen JJ; Smit VT; Creutzberg CL; Bosse T J Natl Cancer Inst; 2015 Jan; 107(1):402. PubMed ID: 25505230 [TBL] [Abstract][Full Text] [Related]
2. Clinicopathological characteristics and prognostic value of POLE mutations in endometrial cancer: A systematic review and meta-analysis. He Y; Wang T; Li N; Yang B; Hu Y Medicine (Baltimore); 2020 Feb; 99(8):e19281. PubMed ID: 32080141 [TBL] [Abstract][Full Text] [Related]
3. The clinicopathology and survival characteristics of patients with POLE proofreading mutations in endometrial carcinoma: A systematic review and meta-analysis. Jumaah AS; Al-Haddad HS; McAllister KA; Yasseen AA PLoS One; 2022; 17(2):e0263585. PubMed ID: 35139130 [TBL] [Abstract][Full Text] [Related]
4. POLE mutation combined with microcystic, elongated and fragmented (MELF) pattern invasion in endometrial carcinomas might be associated with poor survival in Chinese women. He D; Wang H; Dong Y; Zhang Y; Zhao J; Lv C; Zheng X; Li D; Li T Gynecol Oncol; 2020 Oct; 159(1):36-42. PubMed ID: 32800323 [TBL] [Abstract][Full Text] [Related]
9. Mutation spectrum of POLE and POLD1 mutations in South East Asian women presenting with grade 3 endometrioid endometrial carcinomas. Wong A; Kuick CH; Wong WL; Tham JM; Mansor S; Loh E; Jain S; Vikas NN; Tan SH; Chan SH; Li ST; Chew SH; Hong W; Ngeow J Gynecol Oncol; 2016 Apr; 141(1):113-20. PubMed ID: 26748215 [TBL] [Abstract][Full Text] [Related]
10. Evaluation of treatment effects in patients with endometrial cancer and POLE mutations: An individual patient data meta-analysis. McAlpine JN; Chiu DS; Nout RA; Church DN; Schmidt P; Lam S; Leung S; Bellone S; Wong A; Brucker SY; Lee CH; Clarke BA; Huntsman DG; Bernardini MQ; Ngeow J; Santin AD; Goodfellow P; Levine DA; Köbel M; Kommoss S; Bosse T; Gilks CB; Talhouk A Cancer; 2021 Jul; 127(14):2409-2422. PubMed ID: 33793971 [TBL] [Abstract][Full Text] [Related]
11. Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer-Combined Analysis of the PORTEC Cohorts. Stelloo E; Nout RA; Osse EM; Jürgenliemk-Schulz IJ; Jobsen JJ; Lutgens LC; van der Steen-Banasik EM; Nijman HW; Putter H; Bosse T; Creutzberg CL; Smit VT Clin Cancer Res; 2016 Aug; 22(16):4215-24. PubMed ID: 27006490 [TBL] [Abstract][Full Text] [Related]
14. Prognostic Significance of POLE Exonuclease Domain Mutations in High-Grade Endometrioid Endometrial Cancer on Survival and Recurrence: A Subanalysis. Billingsley CC; Cohn DE; Mutch DG; Hade EM; Goodfellow PJ Int J Gynecol Cancer; 2016 Jun; 26(5):933-8. PubMed ID: 26937754 [TBL] [Abstract][Full Text] [Related]
15. Polymerase Epsilon Exonuclease Domain Mutations in Ovarian Endometrioid Carcinoma. Hoang LN; McConechy MK; Köbel M; Anglesio M; Senz J; Maassen M; Kommoss S; Meng B; Postovit L; Kelemen LE; Staebler A; Brucker S; Krämer B; McAlpine JN; Gilks CB; Huntsman DG; Lee CH Int J Gynecol Cancer; 2015 Sep; 25(7):1187-93. PubMed ID: 26166557 [TBL] [Abstract][Full Text] [Related]
16. Endometrial Carcinomas with POLE Exonuclease Domain Mutations Have a Favorable Prognosis. McConechy MK; Talhouk A; Leung S; Chiu D; Yang W; Senz J; Reha-Krantz LJ; Lee CH; Huntsman DG; Gilks CB; McAlpine JN Clin Cancer Res; 2016 Jun; 22(12):2865-73. PubMed ID: 26763250 [TBL] [Abstract][Full Text] [Related]
17. Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study. Domingo E; Freeman-Mills L; Rayner E; Glaire M; Briggs S; Vermeulen L; Fessler E; Medema JP; Boot A; Morreau H; van Wezel T; Liefers GJ; Lothe RA; Danielsen SA; Sveen A; Nesbakken A; Zlobec I; Lugli A; Koelzer VH; Berger MD; Castellví-Bel S; Muñoz J; ; de Bruyn M; Nijman HW; Novelli M; Lawson K; Oukrif D; Frangou E; Dutton P; Tejpar S; Delorenzi M; Kerr R; Kerr D; Tomlinson I; Church DN Lancet Gastroenterol Hepatol; 2016 Nov; 1(3):207-216. PubMed ID: 28404093 [TBL] [Abstract][Full Text] [Related]
18. Clinical impact of endometrial cancer stratified by genetic mutational profiles, POLE mutation, and microsatellite instability. Haruma T; Nagasaka T; Nakamura K; Haraga J; Nyuya A; Nishida T; Goel A; Masuyama H; Hiramatsu Y PLoS One; 2018; 13(4):e0195655. PubMed ID: 29659608 [TBL] [Abstract][Full Text] [Related]
19. Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy. León-Castillo A; de Boer SM; Powell ME; Mileshkin LR; Mackay HJ; Leary A; Nijman HW; Singh N; Pollock PM; Bessette P; Fyles A; Haie-Meder C; Smit VTHBM; Edmondson RJ; Putter H; Kitchener HC; Crosbie EJ; de Bruyn M; Nout RA; Horeweg N; Creutzberg CL; Bosse T; J Clin Oncol; 2020 Oct; 38(29):3388-3397. PubMed ID: 32749941 [TBL] [Abstract][Full Text] [Related]
20. Tumor-infiltrating lymphocytes and POLE mutation in endometrial carcinoma. Raffone A; Travaglino A; Raimondo D; Boccellino MP; Maletta M; Borghese G; Casadio P; Insabato L; Mollo A; Zullo F; Seracchioli R Gynecol Oncol; 2021 May; 161(2):621-628. PubMed ID: 33715893 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]